Last reviewed · How we verify

Idamycin Pfs (Idarubicin Hydrochloride)

Pfizer Inc. · FDA-approved approved Small molecule Quality 61/100

Idamycin Pfs (generic name: Idarubicin Hydrochloride) is a Anthracycline topoisomerase inhibitor Small molecule drug developed by Pfizer Inc.. It is currently FDA-approved (first approved 1990) for Acute myeloid leukemia, disease, Acute promyelocytic leukemia, FAB M3.

Idarubicin forms DNA complexes, inhibits nucleic acid synthesis and topoisomerase II, produces DNA-damaging free radicals.

Idarubicin is an anthracycline topoisomerase inhibitor indicated for adult acute myeloid leukemia as part of combination chemotherapy. The drug demonstrates potent cytotoxic activity through DNA binding, topoisomerase II inhibition, and free radical generation. Idarubicin undergoes extensive metabolism to the active metabolite idarubicinol with sustained plasma levels exceeding 8 days. No contraindications are listed, though effects of renal or hepatic impairment on pharmacokinetics remain unknown.

At a glance

Generic nameIdarubicin Hydrochloride
SponsorPfizer Inc.
Drug classAnthracycline topoisomerase inhibitor
TargetDNA, Topoisomerase II
ModalitySmall molecule
Therapeutic areaOncology
PhaseFDA-approved
First approval1990

Mechanism of action

Idarubicin hydrochloride exhibits antimitotic and cytotoxic activity through multiple mechanisms of action. The drug forms complexes with DNA and inhibits nucleic acid synthesis, preventing cell replication. Additionally, idarubicin inhibits topoisomerase II activity and produces DNA-damaging free radicals, leading to cell death through multiple pathways.

Approved indications

Common side effects

Primary sources

Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.

SourceUsed for
FDA labelMechanism, indications, dosing, boxed warnings, drug interactions

Competitive intelligence

For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:

Frequently asked questions about Idamycin Pfs

What is Idamycin Pfs?

Idamycin Pfs (Idarubicin Hydrochloride) is a Anthracycline topoisomerase inhibitor drug developed by Pfizer Inc., indicated for Acute myeloid leukemia, disease, Acute promyelocytic leukemia, FAB M3.

How does Idamycin Pfs work?

Idarubicin forms DNA complexes, inhibits nucleic acid synthesis and topoisomerase II, produces DNA-damaging free radicals.

What is Idamycin Pfs used for?

Idamycin Pfs is indicated for Acute myeloid leukemia, disease, Acute promyelocytic leukemia, FAB M3.

Who makes Idamycin Pfs?

Idamycin Pfs is developed and marketed by Pfizer Inc. (see full Pfizer Inc. pipeline at /company/pfizer).

What is the generic name of Idamycin Pfs?

Idarubicin Hydrochloride is the generic (nonproprietary) name of Idamycin Pfs.

What drug class is Idamycin Pfs in?

Idamycin Pfs belongs to the Anthracycline topoisomerase inhibitor class. See all Anthracycline topoisomerase inhibitor drugs at /class/anthracycline-topoisomerase-inhibitor.

When was Idamycin Pfs approved?

Idamycin Pfs was first approved on 1990.

What development phase is Idamycin Pfs in?

Idamycin Pfs is FDA-approved (marketed).

What are the side effects of Idamycin Pfs?

Common side effects of Idamycin Pfs include Nausea, Febrile neutropenia, Pyrexia, Platelet count decreased, Vomiting, Diarrhoea.

What does Idamycin Pfs target?

Idamycin Pfs targets DNA, Topoisomerase II and is a Anthracycline topoisomerase inhibitor.

Related